Literature DB >> 28740648

Another disappointing result, but how good is it?

Yasushi Goto1.   

Abstract

Year:  2017        PMID： 28740648      PMCID： PMC5506128          DOI： 10.21037/jtd.2017.05.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

4.  Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

Authors:  Marcello Tiseo; Luca Boni; Francesca Ambrosio; Andrea Camerini; Editta Baldini; Saverio Cinieri; Matteo Brighenti; Francesca Zanelli; Efisio Defraia; Rita Chiari; Claudio Dazzi; Carmelo Tibaldi; Gianni Michele Turolla; Vito D'Alessandro; Nicoletta Zilembo; Anna Rita Trolese; Francesco Grossi; Ferdinando Riccardi; Andrea Ardizzoni
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

5.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

6.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

9.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 10.  Overview: progression-free survival as an endpoint in clinical trials with solid tumors.

Authors:  Ronald L Korn; John J Crowley
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531
View more
  1 in total

1.  Is the door open to further investigation with antiangiogenesis in SCLC?

Authors:  Marcello Tiseo; Luca Boni; Andrea Ardizzoni
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.